Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Trane Technologies plc (TT) vs Viatris Inc (VTRS) Price & Performance

Trane Technologies plcTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Trane Technologies plc vs Viatris Inc — how do they compare? Trane Technologies plc trades at $471.85 (market cap $105.17B), while Viatris Inc trades at $17.59 (market cap $19.81B). The key difference: Trane Technologies plc is far larger — about 5.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.

TTVTRS
Market Cap
$105.17B$19.81B
Volume
1,040,1837,547,542
Sector
IndustrialsHealth
52-Week High
$503.46$18.27
52-Week Low
$376.43$9.98
Enterprise Value
$108.47B$31.92B
Dividend Yield
0.88%2.78%
Typical Hold Time
—57 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Trane Technologies plc

No Aura AI signal available yet.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Trane Technologies plc

Trane Technologies plc is a global climate solutions company that designs, manufactures, and services heating, ventilation, and air conditioning (HVAC) and transport refrigeration equipment under its Trane and Thermo King brands.

Read more on TT →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →